CC
MCRB icon

Corton Capital’s Seres Therapeutics MCRB Stock Holding History

Corton Capital’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,162
Closed -$55.3K – 625
2023
Q3 		$55.3K Sell
1,162
-2,127
-65% -$162K 0.03% 409
2023
Q2 		$315K Buy
+3,289
New +$358K 0.15% 198
2022
Q1 		– Sell
-1,745
Closed -$291K – 457
2021
Q4 		$291K Buy
+1,745
New +$277K 0.13% 167

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Corton Capital's MCRB Position: Q4 2023 in Review

Corton Capital sold out of Seres Therapeutics (MCRB) in Q4 2023, closing a stake of 1,162 shares — an estimated $55.3K sold.

Corton Capital first reported a position in MCRB in Q4 2021 and held it in 3 quarters. The position peaked at $315K in Q2 2023. 102 funds tracked by Wall St. Rank hold MCRB as of Q4 2023.

  • Corton Capital reported no remaining Seres Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Corton Capital sold 1,162 Seres Therapeutics shares in Q4 2023, an estimated $55.3K.
  • Corton Capital first reported a position in Seres Therapeutics in Q4 2021 and held it in 3 quarters.
  • Corton Capital's Seres Therapeutics position peaked at $315K in Q2 2023.
  • 102 funds tracked by Wall St. Rank held Seres Therapeutics as of Q4 2023.

Based on Corton Capital's 13F filing for Q4 2023, filed 14 Feb 2024.